A new vaccine candidate to provide broad protection against pneumonia, developed by a researcher at the University of Oklahoma College of Medicine, is being given to humans for the first time in a Phase I clinical trial.
Potential infection with Clostridioides difficle, or C. difficile, emerges as one of the most troubling risks during a hospital stay, particularly for people taking antibiotics or those with a weakened immune system.